Cabaletta Bio, Inc. 8-K

What Happened
On May 14, 2026 Cabaletta Bio (CABA) filed an 8‑K and issued a press release and updated corporate presentation disclosing clinical and translational data for rese‑cel presented at the ASGCT 2026 meeting. The company reported results from the first four pemphigus vulgaris (RESET‑PV) patients dosed at the lowest preconditioning‑free (PC‑free) rese‑cel dose (all ≥24 weeks follow‑up as of April 2, 2026) and initial data from the first two autoimmune patients whose cells were manufactured on the automated Cellares Cell Shuttle platform (both ≥4 weeks follow‑up as of May 6, 2026).

Key Details

• RESET‑PV PC‑free cohort: four patients dosed at lowest dose; baseline PDAI scores 22–83; all showed early improvement by week 4; two patients maintained drug‑free clinical responses through 6 months.
• Translational/safety markers: three of four patients had complete peripheral B‑cell depletion; anti‑DSG1/DSG3 antibody levels declined; no dose‑limiting toxicities or ICANS; one grade 1 CRS (transient fever).
• Automated manufacturing (Cell Shuttle): first two GMP doses met release specifications and showed product quality (purity, CAR expression, viability, VCN, cytotoxicity) within established clinical ranges; in‑patient expansion and B‑cell depletion kinetics were similar to historical runs.
• Timing: Cabaletta expects higher‑dose PC‑free data from RESET‑PV in 2H26; initial lowest‑dose RESET‑SLE data expected 1H26 (EULAR, June 3–6, 2026).

Why It Matters
These disclosures indicate early signals that rese‑cel may be active without preconditioning in some patients and that automated, closed manufacturing with the Cell Shuttle can reproduce clinical‑grade product attributes. For investors, the items address two material questions for an autologous cell therapy: (1) potential to broaden patient access if PC‑free dosing proves feasible, and (2) potential to scale and control manufacturing cost/consistency if automated production performs as reported. All findings are preliminary and the company notes forward‑looking risks and timelines in the filing.